A Phase II Study. The combination of docetaxel and CPT-11 was found to have encouraging activity in recurrent ovarian cancer. Neutropenia is the main toxicity but it is manageable, while diarrhea is not a problem in the 10 recurrent ovarian cancer patients evaluable for toxicity. Prophylactic glucocorticoids for 3 days was effective in preventing fluid retention. Three of 8 evaluable patients had complete response, and no patient was reported to progress under this treatment.
Additional patients are under study.
Topoisomerase I Activity and Response to Second-Line Chemotherapy Consisting of Camptothecin and Cisplatin in Patients with Ovarian Cancer. I activity is found to be enhanced in certain cisplatinum-resistant ovarian cancer cell lines. This dose escalation study of Irinotecan combined with Carboplatin has not yet progressed to dose-limiting toxicities. No response data are reported. Adenocarcinoma of The Ovary.